search
Back to results

A Study Evaluating AHB-137 in Healthy Participants and Participants With Chronic Hepatitis B

Primary Purpose

Chronic Hepatitis B

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
AHB-137 injection
Placebo
Sponsored by
AusperBio Therapeutics Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Hepatitis B

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Healthy participants are required to meet all the following inclusion criteria in order to be enrolled in the study: 18-65 years old male or female. Body Mass Index (BMI) between 19 to 35 kg/m2 (inclusive) and body weight equal to or over 45 kg. Participants' COVID-19 PCR test should be negative during screening. Participants' COVID-19 Rapid Antigen Test (RAT) should be negative at check-in. CHB patients are required to meet all the following inclusion criteria in order to be enrolled in the study: Have given written informed consent (signed and dated) and any authorizations required by local law and is able to comply with all study requirements. Age 18 to 65 years old. ALT ≤ 5 ULN for CHB patients recruited to Part C; ALT ≤ 2 ULN for CHB patients recruited to Part D. CHB patients who have documented chronic HBV infection equal to or above 6 months prior to screening. Otherwise, CHB patients need to be HBsAg positive and IgM HBcAb negative. CHB patients participating in Part D should have been on commercially available HBV OAV treatment(s) for at least 6 months with no change in regimen for 3 months prior to screening. HBV DNA under limit of quantification (LOQ) at Screening. Both HBeAg positive and negative CHB patients can be recruited to Part C of the study. Only HBeAg negative CHB patients can be recruited to Part D of the study. COVID-19 RAT test should be negative at check-in. Exclusion Criteria: Healthy participants are required to not meet any of the following exclusion criteria in order to be enrolled in the study: Pregnant (positive pregnancy test) or lactating women. Male participants without using proper contraceptives (e.g. condom) with partners who are pregnant or lactating. History or symptoms of any clinically significant gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardio-vascular, endocrinological, hematological or allergic disease, metabolic disorder, cancer or cirrhosis. Personal history of congenital long QT syndrome or family history of sudden cardiac death. Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (non-active hay fever is acceptable). Any clinically significant concomitant diseases or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study. Clinically relevant electrocardiogram (ECG) abnormalities on screening ECG. ECG with QRS and/or T-wave judged to be unfavorable for a consistently accurate QT measurement. Creatinine clearance (CrCl) cutoff ≤ 60 ml/min (using the Cockcroft-Gault formula). Positive test at screening of any of the following: hepatitis A (HAV IgM Ab), hepatitis B (HBsAg), hepatitis C (HCV RNA or HCV Ab), human immunodeficiency virus 1 and 2 (HIV Ab), or TP-Ab. Any other clinically significant abnormalities in laboratory test results at screening. In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility. History of bleeding diathesis or coagulopathy. CHB patients are required to not meet any of the following exclusion criteria in order to be enrolled in the study: History of liver cirrhosis and/or evidence of cirrhosis as determined by any 1 of the following: Liver biopsy (i.e., Metavir Score F4) within 2 years of screening, or FibroScan > 12 KPa, within 12 months of screening, or AST-to-Platelet Index (APRI) > 2 and FibroSure result > 0.7 within 12 months of screening. For patients without a test for cirrhosis in the above timeframes, FibroScan, or APRI and FibroSure, may be performed during the screening period to rule out cirrhosis History of liver failure as evidenced by ascites, hepatic encephalopathy, and/or gastric or esophageal varices. History of liver disease other than hepatitis B. Co-infection with TP, HCV, HIV, or hepatitis D virus (HDV). Body mass index >35 kg/m2 . History or suspected presence of vasculitis . Diagnosed hepatocellular carcinoma or suspected hepatocellular carcinoma as evidenced by screening alpha-fetoprotein ≥200 ng/mL. If the screening alpha-fetoprotein is ≥50 ng/mL and <200 ng/mL, the absence of liver mass must be documented by imaging within 6 months before randomization. Clinically relevant electrocardiogram (ECG) abnormalities on screening ECG. Screening laboratory results as follows, or any other clinically significant abnormalities in screening laboratory values that would render a patient unsuitable for inclusion. ALT > 5 x ULN for Part C or > 2 x ULN for Part D Total bilirubin > 1.25 x ULN Serum albumin < 3.4 g/dL International normalized ratio of prothrombin time > 1.25 Platelet count <140 x 10^9/L Hemoglobin <12.0 g/dL for males and <11.0 g/dL for females White blood cell count <3.0 k/mm3 Serum creatinine >1.1 x ULN Urine protein/creatinine ratio ≥0.2 mg/mg. In the event of a ratio above this threshold, eligibility may be confirmed by a quantitative total urine protein measurement of <150 mg/24 hour Positive test (including trace) for blood on urinalysis. In the event of a positive test, eligibility may be confirmed with urine microscopy showing <5 red blood cells per high power field Clinically significant abnormalities and/or poorly controlled medical conditions (e.g. Cardiovascular, pulmonary, metabolic disease) in the opinion of the investigator. History of bleeding diathesis or coagulopathy. History of extrahepatic disorders possibly related to HBV immune complexes (e.g., glomerulonephritis, polyarteritis nodosa) . Active infection other than HBV, requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day 1.

Sites / Locations

  • American Research Corporation
  • New Zealand Clinical ResearchRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Part A: SAD in healthy participants

Part B: MD in healthy participants

Part C: MD in CHB patients (open label)

Part D: MD in CHB patients in multiple centers

Arm Description

Part A: Single ascending doses of up to 450 mg AHB-137 by subcutaneous (SC) injection in healthy participants.

Part B: Multiple doses of 300 mg AHB-137 by subcutaneous (SC) injection in healthy participants.

Part C: Multiple doses of 300 mg AHB-137 by subcutaneous (SC) injection in CHB patients.

Part D: Multiple doses of 200 mg or 300 mg AHB-137 by subcutaneous (SC) injection in CHB patients (Multiple centers across multiple regions).

Outcomes

Primary Outcome Measures

Proportion of Participants With Treatment-Emergent Adverse Events (TEAEs) in Healthy Volunteers
Proportion of Participants With Treatment-Emergent Adverse Events (TEAEs) in CHB patients

Secondary Outcome Measures

The anti-HBV efficacy of AHB-137: evaluate the change in serum HBsAg (log10 IU/mL) from baseline.
The anti-HBV efficacy of AHB-137: evaluate the expression of HBsAb in serum.
The pharmacokinetic profile of AHB-137: the maximum observed plasma concentration (Cmax) of AHB-137
The pharmacokinetic profile of AHB-137: time of observed maximal concentration (Tmax) of AHB-137
The pharmacokinetic profile of AHB-137: areas under the concentration time curve (AUC) of AHB-137
The pharmacokinetic profile of AHB-137: mean residence time (MRT) of AHB-137
The pharmacokinetic profile of AHB-137: terminal half-life (t1/2) of AHB-137
The pharmacokinetic profile of AHB-137: apparent subcutaneous plasma clearance (CL/F) of AHB-137
The pharmacokinetic profile of AHB-137: amount of AHB-137 excreted in urine (Ae)
The pharmacokinetic profile of AHB-137: renal clearance (CLr) of AHB-137

Full Information

First Posted
January 20, 2023
Last Updated
October 5, 2023
Sponsor
AusperBio Therapeutics Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05717686
Brief Title
A Study Evaluating AHB-137 in Healthy Participants and Participants With Chronic Hepatitis B
Official Title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AHB-137 With Single Ascending Doses and Multiple Doses in Healthy Volunteers and Initial Efficacy in Chronic Hepatitis B Patients
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 28, 2023 (Actual)
Primary Completion Date
August 31, 2024 (Anticipated)
Study Completion Date
January 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AusperBio Therapeutics Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy volunteers and in chronic hepatitis B (CHB) patients after single and multiple doses. In addition, the study will evaluate the initial antiviral efficacy of AHB-137 in CHB patients following a multiple dosing regimen.
Detailed Description
This is a first-in-human study of AHB-137, consisting of four parts. Parts A and B are randomized, double-blinded, placebo-controlled studies designed to assess the safety, tolerability, pharmacokinetics of AHB-137 following subcutaneous injection in healthy volunteers at a 6:2 ratio of AHB-137 to placebo. Part A is a single-ascending dose (SAD) study, and Part B is a single-ascending dose (SAD) study, and Part B is a multiple dose (MD) study. Part C is an open label MD study with up to 6 CHB patients. Part D is a double blinded study in CHB patients at a 4:1 ratio to receive AHB-137 or placebo. Study advancement to subsequent parts/cohorts will require satisfactory interim reviews of available cumulative safety data by the Safety Review Committees (SRC), using the safety criteria and review procedures described in the protocol.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Hepatitis B

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
90 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part A: SAD in healthy participants
Arm Type
Experimental
Arm Description
Part A: Single ascending doses of up to 450 mg AHB-137 by subcutaneous (SC) injection in healthy participants.
Arm Title
Part B: MD in healthy participants
Arm Type
Experimental
Arm Description
Part B: Multiple doses of 300 mg AHB-137 by subcutaneous (SC) injection in healthy participants.
Arm Title
Part C: MD in CHB patients (open label)
Arm Type
Experimental
Arm Description
Part C: Multiple doses of 300 mg AHB-137 by subcutaneous (SC) injection in CHB patients.
Arm Title
Part D: MD in CHB patients in multiple centers
Arm Type
Experimental
Arm Description
Part D: Multiple doses of 200 mg or 300 mg AHB-137 by subcutaneous (SC) injection in CHB patients (Multiple centers across multiple regions).
Intervention Type
Drug
Intervention Name(s)
AHB-137 injection
Intervention Description
AHB-137 will be administered
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo will be administered
Primary Outcome Measure Information:
Title
Proportion of Participants With Treatment-Emergent Adverse Events (TEAEs) in Healthy Volunteers
Time Frame
Up to 30 days for SAD, up to 113 days for MD
Title
Proportion of Participants With Treatment-Emergent Adverse Events (TEAEs) in CHB patients
Time Frame
Up to 204 days for MD
Secondary Outcome Measure Information:
Title
The anti-HBV efficacy of AHB-137: evaluate the change in serum HBsAg (log10 IU/mL) from baseline.
Time Frame
Up to 204 days
Title
The anti-HBV efficacy of AHB-137: evaluate the expression of HBsAb in serum.
Time Frame
Up to 204 days
Title
The pharmacokinetic profile of AHB-137: the maximum observed plasma concentration (Cmax) of AHB-137
Time Frame
Up to 30 days for SAD; up to 204 days for MD
Title
The pharmacokinetic profile of AHB-137: time of observed maximal concentration (Tmax) of AHB-137
Time Frame
Up to 30 days for SAD; up to 204 days for MD
Title
The pharmacokinetic profile of AHB-137: areas under the concentration time curve (AUC) of AHB-137
Time Frame
Up to 30 days for SAD; up to 204 days for MD
Title
The pharmacokinetic profile of AHB-137: mean residence time (MRT) of AHB-137
Time Frame
Up to 30 days for SAD; up to 204 days for MD
Title
The pharmacokinetic profile of AHB-137: terminal half-life (t1/2) of AHB-137
Time Frame
Up to 30 days for SAD; up to 204 days for MD
Title
The pharmacokinetic profile of AHB-137: apparent subcutaneous plasma clearance (CL/F) of AHB-137
Time Frame
Up to 30 days for SAD; up to 204 days for MD
Title
The pharmacokinetic profile of AHB-137: amount of AHB-137 excreted in urine (Ae)
Time Frame
Day 1-4 for SAD; Day 1-4 and Day 22-25 for MD
Title
The pharmacokinetic profile of AHB-137: renal clearance (CLr) of AHB-137
Time Frame
Day 1-4 for SAD; Day 1-4 and Day 22-25 for MD

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy participants are required to meet all the following inclusion criteria in order to be enrolled in the study: 18-65 years old male or female. Body Mass Index (BMI) between 19 to 35 kg/m2 (inclusive) and body weight equal to or over 45 kg. Participants' COVID-19 PCR test should be negative during screening. Participants' COVID-19 Rapid Antigen Test (RAT) should be negative at check-in. CHB patients are required to meet all the following inclusion criteria in order to be enrolled in the study: Have given written informed consent (signed and dated) and any authorizations required by local law and is able to comply with all study requirements. Age 18 to 65 years old. ALT ≤ 5 ULN for CHB patients recruited to Part C; ALT ≤ 2 ULN for CHB patients recruited to Part D. CHB patients who have documented chronic HBV infection equal to or above 6 months prior to screening. Otherwise, CHB patients need to be HBsAg positive and IgM HBcAb negative. CHB patients participating in Part D should have been on commercially available HBV OAV treatment(s) for at least 6 months with no change in regimen for 3 months prior to screening. HBV DNA under limit of quantification (LOQ) at Screening. Both HBeAg positive and negative CHB patients can be recruited to Part C of the study. Only HBeAg negative CHB patients can be recruited to Part D of the study. COVID-19 RAT test should be negative at check-in. Exclusion Criteria: Healthy participants are required to not meet any of the following exclusion criteria in order to be enrolled in the study: Pregnant (positive pregnancy test) or lactating women. Male participants without using proper contraceptives (e.g. condom) with partners who are pregnant or lactating. History or symptoms of any clinically significant gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardio-vascular, endocrinological, hematological or allergic disease, metabolic disorder, cancer or cirrhosis. Personal history of congenital long QT syndrome or family history of sudden cardiac death. Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (non-active hay fever is acceptable). Any clinically significant concomitant diseases or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study. Clinically relevant electrocardiogram (ECG) abnormalities on screening ECG. ECG with QRS and/or T-wave judged to be unfavorable for a consistently accurate QT measurement. Creatinine clearance (CrCl) cutoff ≤ 60 ml/min (using the Cockcroft-Gault formula). Positive test at screening of any of the following: hepatitis A (HAV IgM Ab), hepatitis B (HBsAg), hepatitis C (HCV RNA or HCV Ab), human immunodeficiency virus 1 and 2 (HIV Ab), or TP-Ab. Any other clinically significant abnormalities in laboratory test results at screening. In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility. History of bleeding diathesis or coagulopathy. CHB patients are required to not meet any of the following exclusion criteria in order to be enrolled in the study: History of liver cirrhosis and/or evidence of cirrhosis as determined by any 1 of the following: Liver biopsy (i.e., Metavir Score F4) within 2 years of screening, or FibroScan > 12 KPa, within 12 months of screening, or AST-to-Platelet Index (APRI) > 2 and FibroSure result > 0.7 within 12 months of screening. For patients without a test for cirrhosis in the above timeframes, FibroScan, or APRI and FibroSure, may be performed during the screening period to rule out cirrhosis History of liver failure as evidenced by ascites, hepatic encephalopathy, and/or gastric or esophageal varices. History of liver disease other than hepatitis B. Co-infection with TP, HCV, HIV, or hepatitis D virus (HDV). Body mass index >35 kg/m2 . History or suspected presence of vasculitis . Diagnosed hepatocellular carcinoma or suspected hepatocellular carcinoma as evidenced by screening alpha-fetoprotein ≥200 ng/mL. If the screening alpha-fetoprotein is ≥50 ng/mL and <200 ng/mL, the absence of liver mass must be documented by imaging within 6 months before randomization. Clinically relevant electrocardiogram (ECG) abnormalities on screening ECG. Screening laboratory results as follows, or any other clinically significant abnormalities in screening laboratory values that would render a patient unsuitable for inclusion. ALT > 5 x ULN for Part C or > 2 x ULN for Part D Total bilirubin > 1.25 x ULN Serum albumin < 3.4 g/dL International normalized ratio of prothrombin time > 1.25 Platelet count <140 x 10^9/L Hemoglobin <12.0 g/dL for males and <11.0 g/dL for females White blood cell count <3.0 k/mm3 Serum creatinine >1.1 x ULN Urine protein/creatinine ratio ≥0.2 mg/mg. In the event of a ratio above this threshold, eligibility may be confirmed by a quantitative total urine protein measurement of <150 mg/24 hour Positive test (including trace) for blood on urinalysis. In the event of a positive test, eligibility may be confirmed with urine microscopy showing <5 red blood cells per high power field Clinically significant abnormalities and/or poorly controlled medical conditions (e.g. Cardiovascular, pulmonary, metabolic disease) in the opinion of the investigator. History of bleeding diathesis or coagulopathy. History of extrahepatic disorders possibly related to HBV immune complexes (e.g., glomerulonephritis, polyarteritis nodosa) . Active infection other than HBV, requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day 1.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bella Lu
Phone
+8615968607969
Email
bingxia.lu@ausperbio.com
First Name & Middle Initial & Last Name or Official Title & Degree
Chen Yang
Phone
+8613022101528
Email
chen.yang@ausperbio.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ed Gane
Organizational Affiliation
University of Auckland, New Zealand
Official's Role
Principal Investigator
Facility Information:
Facility Name
American Research Corporation
City
Houston
State/Province
Texas
ZIP/Postal Code
78215
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
New Zealand Clinical Research
City
Grafton
State/Province
Auckland
ZIP/Postal Code
1010
Country
New Zealand
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study Evaluating AHB-137 in Healthy Participants and Participants With Chronic Hepatitis B

We'll reach out to this number within 24 hrs